| Literature DB >> 29572396 |
Shona Mackinnon1, Bogna A Drozdowska2, Michael Hamilton3, Anna H Noel-Storr4, Rupert McShane4, Terry Quinn2.
Abstract
OBJECTIVE: To determine whether methodological and reporting quality are associated with surrogate measures of publication impact in the field of dementia biomarker studies.Entities:
Keywords: QUADAS; STARD; biomarker; citations; dementia; journal impact factor
Mesh:
Substances:
Year: 2018 PMID: 29572396 PMCID: PMC5875624 DOI: 10.1136/bmjopen-2017-020331
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Descriptive statistics of study level and impact data
| QUADAS score (range 0–14), mean (±SD) | 8.9 (±1.5) |
| STARD score (range 0–25), mean (±SD) | 16.1 (±4.0) |
| Baseline sample size, mean (±SD) | 171.3 (±288.2) |
| No. of participants with dementia at end of study, mean (±SD) | 47.3 (±50.4) |
| Report on biomarker accuracy, n (%) | 52 (36.6) |
| Statement on COI, n (%) | 52 (36.6) |
| CSF biomarker, n (%) | 56 (39.4) |
| Imaging biomarker, n (%) | 102 (71.8) |
| ADNI study population, n (%) | 11 (7.7) |
| North American study location, n (%) | 60 (42.3) |
| Pharmaceutical funding source, n (%) | 12 (8.5) |
| Neuroscientific journal, n (%) | 85 (59.9) |
| Positive authors’ conclusions, n (%) | 122 (85.9) |
| No. of years since publication, mean (±SD) | 9.1 (±3.0) |
| Average no. of citations per year, mean (±SD) | 12.8 (±15.5) |
| 5-year journal impact factor, mean (±SD) | 6.1 (±3.9) |
*Data from 141 studies.
ADNI, Alzheimer’s Disease Neuroimaging Initiative; COI, conflict of interest; CSF, cerebrospinal fluid; QUADAS, Quality Assessment of Diagnostic Accuracy Studies checklist; STARD, Standards for Reporting of Diagnostic Accuracy checklist.
Univariable associations between publication and journal characteristics and measures of impact
| Average citations per year | 5-year journal impact factor | |||
| Effect size (r) | P value | Effect size (r) | P value | |
| QUADAS score | 0.12 | 0.144 | 0.04 | 0.670 |
| STARD score | 0.18 | 0.035 | 0.02 | 0.797 |
| Baseline sample size | 0.05 | 0.522 | 0.17 | 0.040 |
| No. of participants with dementia at end of study | 0.11 | 0.190 | 0.13 | 0.120 |
| Report on biomarker accuracy | 0.11 | 0.187 | 0.07 | 0.384 |
| Statement on COI | 0.11 | 0.204 | 0.28 | 0.001 |
| CSF biomarker | 0.07 | 0.410 | 0.04 | 0.646 |
| Imaging biomarker | 0.09 | 0.301 | 0.10 | 0.251 |
| ADNI population | 0.17 | 0.046 | 0.21 | 0.012 |
| Continent | 0.19 | 0.024 | 0.29 | 0.001 |
| Funding | 0.15 | 0.084 | 0.18 | 0.031 |
| Journal subject area | 0.46 | <0.001 | 0.28 | 0.001 |
| Authors’ conclusions | 0.03 | 0.707 | 0.06 | 0.500 |
| No. of years since publication | −0.32 | <0.001 | −0.05 | 0.562 |
| Average no. of citations per year | – | – | 0.63 | <0.001 |
| 5-year journal impact factor | 0.63 | <0.001 | – | – |
*P value indicating a significant association after applying a Holm-Bonferroni correction.
ADNI, Alzheimer’s Disease Neuroimaging Initiative; COI, conflict of interest; CSF, cerebrospinal fluid; QUADAS, Quality Assessment of Diagnostic Accuracy Studies checklist; STARD, Standards for Reporting of Diagnostic Accuracy checklist.